ESMO 2022 | Unmet needs in treating oligometastatic prostate cancer

Nicholas James, MBBS, PhD, FRCP, FRCR, The Royal Marsden NHS Foundation Trust, London, UK, comments on treatment outcomes for patients who have recurrent oligometastatic prostate cancer, which can be divided into synchronous or metachronous and low or high volume type metastases. Patients with high volume synchronous or metachronous prostate cancer tend to have poorer outcomes and further research is needed to assess what the appropriate treatment strategy is for these subset of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.